A retrospective, observational, multicenter study in patients with advanced urothelial carcinoma after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status
Latest Information Update: 14 Oct 2020
At a glance
- Drugs Erdafitinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 14 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress